Kinase Domain Point Mutations in Ph+ Acute Lymphoblastic Leukemia (ALL) Emerge Following Therapy with BCR-ABL Kinase Inhibitors

類似資料

• Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
  著者:: Jabbour, Elias, 等
  出版事項: (2012)
• Mutant BCR-ABL clones in chronic myeloid leukemia
  著者:: Mathisen, Michael S., 等
  出版事項: (2011)
• Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
  著者:: Jabbour, Elias, 等
  出版事項: (2008)
• Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
  著者:: Jabbour, Elias, 等
  出版事項: (2012)
• Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
  著者:: Jabbour, Elias, 等
  出版事項: (2010)